↓ Cooling
Business
Eli Lilly takes aim at illicit market for its experimental weight-loss drug
Eli Lilly sues six firms to shut down a black‑market trade in its experimental obesity drug retatrutide.
Eli Lilly
6 independently sourced, verified news trends involving Eli Lilly.
Coverage evidence
This hub is built from stories supported by at least four independent sources and accepted by Newsylist's verification pass. Qualifying coverage spans 1 news category, from Jun 26, 2026 through Aug 12, 2026.
Open any card for the source list, timeline and coverage-velocity evidence. Raw detections and extractive-only records are excluded from this page.
◼ Archived
Business
🔮 holds ✓
Eli Lilly delays FDA filing for next-generation weight-loss drug retatrutide
Eli Lilly is planning a Q1 2027 FDA application for retatrutide following new data on weight loss and A1C improvements.
◼ Archived
Business
🔮 holds ✓
Novo sues Lilly, claiming misleading ads in weight-loss drug battle
Novo Nordisk has filed a lawsuit against Eli Lilly over allegations of false and misleading advertising regarding weight-loss drug efficacy.
◼ Archived
Business
🔮 fades ✗
Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising
Novo Nordisk has filed a lawsuit against Eli Lilly, alleging the company used deceptive and false advertising regarding GLP-1 weight-loss medications.
◼ Archived
Business
🔮 fades ✓
Lilly Said to Near Deal for Psychedelic Drugmaker AtaiBeckley
Eli Lilly is reportedly nearing an acquisition of the psychedelic drugmaker AtaiBeckley, triggering significant movement in the company's share price.
◼ Archived
Business
🔮 holds ✗
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2026
Eli Lilly shares surge following a CHMP recommendation for Jaypirca's EU approval to treat chronic lymphocytic leukemia.